Nocturia: A non-specific but important symptom of urological disease

International Journal of Urology

Volumn 16, Issue 3, 2009, Pages 249-256

  Schneider, Tim ^b   De La Rosette, Jean Jmch ^a   Michel, Martin C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Praxisklinik Urologie Rhein Ruhr   (Germany)

Author keywords

1 adrenoceptor antagonists; Desmopressin; Muscarinic receptor antagonists; Nocturia

Indexed keywords

ALFUZOSIN; DARIFENACIN; DESMOPRESSIN; DICLOFENAC; DULOXETINE; FESOTERODINE; FINASTERIDE; LOXOPROFEN; NAFTOPIDIL; SOLIFENACIN; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER CANCER; BLADDER CAPACITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG DOSE TITRATION; ENURESIS; FLUID INTAKE; HUMAN; HYPOALBUMINEMIA; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIFESTYLE; LOWER URINARY TRACT SYMPTOM; MEDICAL ASSESSMENT; MICTURITION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NOCTURIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; POLYURIA; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; REVIEW; SLEEP APNEA SYNDROME; URINARY TRACT DISEASE;

DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; NOCTURIA; PREDICTIVE VALUE OF TESTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE; URODYNAMICS; UROLOGIC DISEASES;

EID: 62149130014     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02246.x     Document Type: Review

References (115)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff JW, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 87 : 760 6.
2. van Kerrebroeck P, Abrams P, Chaikin D et al. The standardisation of terminology in nocturia: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. 2002 21 : 179 83.
3. Middelkoop HA, Smilde-van den Doel DA, Neven AK, Kamphuisen HA, Springer CP. Subjective sleep characteristics of 1485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. J. Gerontol. A Biol. Sci. Med. Sci. 1996 51 : M108 15.
4. Stewart WF, van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003 20 : 327 36.
5. Yoshimua K, Terada N, Matsui Y, Terai A, Kinukawa N, Arai Y. Prevalence and risk factors for nocturia: analysis of a health screnning program. Int. J. Urol. 2004 11 : 282 7.
6. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur. Urol. 2005 48 : 622 7.
7. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006 50 : 1306 15.
8. Abrams P. Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur. Urol. Suppl. 2005 3 : 8 16.
9. Homma Y, Imajo C, Takahashi S, Kawabe K, Aso Y. Urinary symptoms and urodynamics in a normal elderly population. Scand. J. Urol. Nephrol. 1994 157 : 27 30.
10. Schatzl G, Temml C, Schmidbauer J, Dolezal B, Haidinger G, Madersbacher S. Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology 2000 56 : 71 5.
11. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003 92 : 948 54.
12. Tikkinen KAO, Tammela TLJ, Huhtala H, Auvinen A. Is nocturia equally common among men and women? A population based study in Finland. J. Urol. 2006 175 : 596 600.
13. Lapitan MC, Chye PLH. The epidemiology of overactive bladder among females in Asia: a questionnaire study. Int. Urogynecol. J. 2001 12 : 226 31.
14. Goepel M, Hoffmann J, Piro M, Rübben H, Michel MC. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur. Urol. 2002 41 : 234 9.
15. Homma Y. Lower urinary tract symptomatology: its definition and confusion. Int. J. Urol. 2008 15 : 35 43.
16. Abraham L, Hareendran A, Mills IW et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004 63 : 481 6.
17. Cai T, Gardener N, Abraham L, Boddi V, Abrams P, Bartoletti R. Impact of surgical treatment on nocturia in men with benign prostatic obstruction. BJU Int. 2006 98 : 799 805.
18. Bing MH, Moller LA, Jennum P, Mortensen S, Lose G. Validity and reliability of a questionnaire for evaluating nocturia, nocturnal enuresis and sleep-interruptions in an elderly population. Eur. Urol. 2006 49 : 710 19.
19. Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur. Urol. Suppl. 2005 4 : 61 8.
20. Homma Y, Yoshida M, Yamanishi T, Gotoh M. Core lower urinary tract symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int. J. Urol. 2008 15 : 816 20.
21. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008 102 : 62 6.
22. Tani M, Hirayama A, Fujimoto K, Torimoto K, Akiyama T, Hirao Y. Increase in 24-hour urine production/weight causes nocturnal polyuria due to impaired function of antidiuretic hormone in elderly men. Int. J. Urol. 2008 15 : 151 5.
23. Ishikawa S-E. Cellular actions of arginine vasopressin in the kidney. Endocr. J. 1993 40 : 373 86.
24. de Zeeuw D, Janssen WMT, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int. 1992 41 : 1115 33.
25. Insel PA, Tang C-M, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: genetic variants and drug targets. Biochim. Biophys. Acta 2007 1768 : 994 1005.
26. Gourova LW, van den Beek C, Spigt MG, Nieman FH, van Kerrebroeck PE. Predictive factors for nocturia in elderly men: a cross-sectional study in 21 general practices. BJU Int. 2006 97 : 528 32.
27. Hsieh CH, Chen HY, Hsu CS, Chang ST, Chiang CD. Risk factors for nocturia in Taiwanese women aged 20-59 years. Taiwan J. Obstet. Gynecol. 2007 46 : 166 70.
28. Paick J-S, Kim SW, Oh S-J, Ku JH. Voiding patterns in men and women with lower urinary tract symptoms combined with nocturia. Int. J. Urol. 2007 14 : 699 703.
29. Mariappan P, Turner KJ, Sothilingam S, Rajan P, Sundram M, Stewart LH. Nocturia, nocturia indices and variables from frequency-volume charts are significantly different in Asian and Caucasian men with lower urinary tract symptoms: a prospective comparison study. BJU Int. 2007 100 : 332 6.
30. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005 95 : 335 40.
31. Bulmer P, Abrams P. The unstable detrusor. Urol. Int. 2004 72 : 1 12.
32. Weiss JP, Blaivas JG. Nocturia. Curr. Urol. Rep. 2005 4 : 362 6.
33. Susset JG, Servot-Viguier D, Lamy F, Madernas P, Black R. Collagen in 155 human bladders. Invest. Urol. 1978 16 : 204 6.
34. Umlauf MG, Chasens ER. Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med. Rev. 2003 7 : 403 11.
35. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc. Res. 2005 68 : 8 17.
36. Lowenstein L, Kenton K, Brubaker L et al. The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women. Am. J. Obstet. Gynecol. 2008 198 : 598.e1 5.
37. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron 2001 87 : 8 18.
38. Makaryus AN, McFarlane SI. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve. Clin. J. Med. 2006 73 : 65 71.
39. Menefee LA, Cohen MJ, Anderson WR, Doghramji K, Frank ED, Lee H. Sleep disturbance and non-malignant chronic pain: a comprehensive review of the literature. Pain Med. 2000 1 : 156 72.
40. Roehrs T, Roth T. Sleep and pain: interaction of two vital functions. Semin. Neurol. 2005 25 : 106 16.
41. Anderson RT, Rajagopalan R. Effects of allergic dermatosis on health-related quality of life. Curr. Allergy Asthma Rep. 2001 1 : 309 15.
42. Asplund R, Henriksson S, Johansson S, Isacsson G. Nocturia and depression. BJU Int. 2004 93 : 1253 6.
43. Shiri R, Hakama M, Häkkinen J et al. The effects of lifestyle factors on the incidence of nocturia. J. Urol. 2008 180 : 2059 62.
44. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T. Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. J. Urol. 2002 167 : 172 6.
45. Peters TJ, Donovan JL, Kay HE et al. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the bothersomeness of urinary symptoms. J. Urol. 1997 157 : 885 9.
46. Mitroupoulos D, Anastasiou I, Giannopoulo C, Nikolopoulos G, Alamanis C, Zervas A. Symptomatic benign prostatic hyperplasia: impact on partners' quality of life. Eur. Urol. 2002 41 : 240 5.
47. Johnson TM II., Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study trial. J. Urol. 2003 170 : 145 8.
48. Seki N, Yunoki T, Tomoda T, Takei M, Yamaguchi A, Naito S. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate. Neurourol. Urodyn. 2008 27 : 222 5.
49. Ushijima S, Ukimura O, Okihara K, Mizutani Y, Kawauchi A, Miki T. Visual analog scale questionnaire to assess the quality of life specific to each symptom of the International Prostate Symptom Score. J. Urol. 2006 176 : 665 71.
50. van Dijk MM, Wijkstra H, de la Rosette JJMCH, Michel MC. Role of nocturia for the quality of life of patients with benign prostatic hyperplasia. Urology 2006 68 (Suppl 5A 109.
51. Batista-Miranda JE, Molinuevo B, Pardo Y. Impact of lower urinary tract symptoms on quality of life using functional assessment cancer therapy scale. Urology 2007 69 : 285 8.
52. Michel MC, Schumacher H, Mehlburger L, de la Rosette JJMCH. The impact of nocturia on signs and symptoms associated with benign prostatic hyperplasia. Urology 2006 68 (Suppl 5A 109 10.
53. Irwin DE, Abrams P, Milstien S, Kopp Z, Reillly K. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008 101 : 1381 7.
54. Asplund R, Aberg H. Nocturnal micturition, sleep and well-being in women of ages 40-65 years. Maturitas 1996 24 : 73 81.
55. Asplund R. Sleep disorders in the elderly. Drugs Aging 1999 14 : 91 103.
56. Diefenbach K, Jaeger K, Wollny A, Penzel T, Fietze I, Roots I. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med. 2008 9 : 579 82.
57. Diefenbach K, Arold G, Wollny A, Schwantes U, Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged >50 years. BJU Int. 2005 95 : 346 9.
58. Diefenbach K, Donath F, Maurer A et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin. Drug Investig. 2003 23 : 395 404.
59. Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur. Urol. Suppl. 2005 3 : 24 32.
60. Schneider T, Stanley N. The impact of nocturia on sleep and energy. Eur. Urol. Suppl. 2007 6 : 585 93.
61. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int. 1999 84 : 297 301.
62. Akerstedt T, Nilsson PM. Sleep restitution: an introduction. J. Intern. Med. 2003 254 : 6 12.
63. Bonnet MH, Arand DL. Clinical effects of sleep fragmentation versus sleep deprivation. Sleep Med. Rev. 2003 7 : 297 310.
64. Bursztyn M, Jacob J, Stessman J. Usefulness of nocturia as a mortality risk factor for coronary heart disease among persons born in 1920 or 1921. Am. J. Cardiol. 2006 98 : 1311 15.
65. Eckford SD, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br. J. Urol. 1994 74 : 733 5.
66. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch. Neurol. 1996 53 : 1270 5.
67. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 1983 46 : 854 5.
68. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand. J. Urol. Nephrol. 1990 24 : 109 12.
69. Fredrikson S. Nasal spray desmopressin in treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol. Scand. 1996 94 : 31 4.
70. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 1998 65 : 778 80.
71. Cvetkovic RS, Plosker GL. Desmopressin in adults with nocturia. Drugs 2005 65 : 99 107.
72. Zahariou A, Karagiannis G, Papaionnou P, Stathi K, Michail X. The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura. Medicophys. 2007 43 : 333 8.
73. Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int. 1999 83 : 591 5.
74. Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br. J. Urol. 1982 54 : 252 5.
75. Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int. 1999 84 : 20 4.
76. Mattiasson A, Abrams P, van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002 89 : 855 62.
77. Lose G, Lalos O, Freeman RM, van Kerrebroeck P. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am. J. Obstet. Gynecol. 2003 189 : 1106 13.
78. van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff JW, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur. Urol. 2007 52 : 221 9.
79. Lose G, Mattiasson A, Walter S et al. Clinical experience with desmopressin for long-term treatment of nocturia. J. Urol. 2004 172 : 1021 5.
80. Johnson TM II., Miller M, Tang T, Pillion DJ, Ouslander JG. Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study. J. Am. Med. Dir. Assoc. 2006 7 : 6 11.
81. Chancellor MB, Atan A, Rivas DA, Watanabe T, Tai HL, Kumon H. Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results. Tech. Urol. 1999 5 : 191 4.
82. Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int. 2004 93 : 996 1000.
83. Hashim H, Malmberg L, Graugaard-Jensen C, Abrams P. Desmopressin, as a 'designer-drug,' in the treatment of overactive bladder syndrome. Neurourol. Urodyn. 2009 28 : 40 6.
84. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991 337 : 1457 61.
85. Roehrborn C, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003 92 : 257 61.
86. Chapple CR, Carter P, Christmas TJ et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br. J. Urol. 1994 74 : 50 6.
87. 1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006 97 : 747 51.
88. 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br. J. Urol. 1995 76 : 325 36.
89. Debruyne FMJ, Witjes WPJ, Fitzpatrick J, Kirby R, Kirk D, Prezioso D. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur. Urol. 1996 30 : 369 76.
90. Paick J-S, Ku JH, Shin JW, Yang JH, Kim SW. α-Blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int. 2006 97 : 1017 23.
91. Kirby RS, Coppinger MO, Chapple CR, Flannigan M, Milrov EJ. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br. J. Urol. 1987 60 : 136 42.
92. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an α1-blocker, YM 617, in the treatment of benign prostatic hypertrophy. J. Urol. 1990 144 : 908 12.
93. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur. Urol. 1996 29 : 155 67.
94. Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19 365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J. Urol. 1998 160 : 784 91.
95. Michel MC, de la Rosette JJMCH, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur. Urol. 2005 48 : 110 15.
96. Chapple CR, Khullar V, Gabriel Z, Muston D, Biton CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 2008 54 : 543 62.
97. Lee K-S, Lee HW, Han DH. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch. Pharmacol. 2008 377 : 491 501.
98. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. 2004 45 : 420 9.
99. 3-selective receptor antagonist. BJU Int. 2005 95 : 580 6.
100. Chapple C, van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur. Urol. 2007 52 : 1204 12.
101. Nitti VW, Dmochowski R, Sand PK et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J. Urol. 2007 178 : 2488 94.
102. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004 93 : 303 10.
103. Gittelman MC. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int. J. Gynecol. Obstet. 2003 83 (Suppl 3 94.
104. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. 2004 172 : 1919 24.
105. Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. 2006 97 : 1262 6.
106. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 67 : 731 6.
107. Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int. J. Clin. Pract. 2006 60 : 752 8.
108. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006 68 : 328 32.
109. Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J. Urol. 2004 171 : 2311 15.
110. Michel MC, de la Rosette JJMCH. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int. 2005 96 (Suppl 1 37 42.
111. Rovner ES, Kreder K, Sussman DO et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J. Urol. 2008 180 : 1034 41.
112. Addla SK, Adeyoju AB, Neilson D, O'Reilly P. Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blin, placebo-controlled cross-over study. Eur. Urol. 2006 49 : 720 6.
113. Okada S, Watanabe H, Kojima Y, Yanai Y, Sasaki S, Kohri K. Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on night-time urine production. Int. J. Urol. 2008 15 : 462 4.
114. Steers WD, Herschorn S, Kreder KJ et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007 100 : 337 45.
115. Seki N, Yuki K, Takei M, Yamaguchi A, Naito S. Analysis of the prognostic factors for overactive bladder symptoms following surgical tratment in patients with benign prostatic obstruction. Neurourol. Urodyn. 2009 (in press).